Ricevi le ultime notizie sulle azioni Lyell Immunopharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LYEL

Ultime notizie per

LYELL IMMUNOPHARMA INC

Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Lyell Immunopharma Inc

Earnings

Press Releases

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

News

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

General

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series

Financing

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Small Cap

Opinion

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Lyell Immunopharma Announces Participation in September Investor Conferences

Health Care

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

AGEN

CELC

EVAX

LYEL

ONCY

TSX:ONC

AC Immune

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Altimmune

Annexon

Aura Biosciences

Benitec Biopharma

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Editas Medicine

enGene Holdings

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immutep Limited - American Depositary Shares

Immutep

Invivyd

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Neurogene

PepGen

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

LUCID CAPITAL MARKETS

HC Wainwright & Co.

B of A Securities

JP Morgan

Morgan Stanley

Comments

Lyell Immunopharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO